AlloCure Lands $1,501,500 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    25 Corporate Dr. Burlington, MA 01803
  • Company Description
    Allocure is poised to be the first company to develop viable cell therapies for the effective treatment of many serious and debilitating medical conditions. AlloCure’s cell therapies represent a novel and proprietary class of biological therapeutics that will change the way a number of serious illnesses are treated. AlloCure’s most advanced therapies target acute kidney injury (AKI), kidney transplantation and multi organ failure. AlloCure’s Phase I Clinical Trial for AKI will begin in July of 2008.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy